Top

Published in:

01-02-2009 | Original Article

Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma

Authors: Geng-Wen Huang, Yi-Ming Tao, Xiang Ding

Published in: Digestive Diseases and Sciences | Issue 2/2009

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in China. We aimed to first present the expression of endocan in HCC tissue and its correlation with the clinicopathological features and overall survival of patients with HCC after curative hepatectomy. Immunohistochemical detection of endocan, CD34, and vascular endothelial growth factor (VEGF) were performed on samples from 100 patients with HCC. Endocan protein was expressed in endothelium of HCC tissue in all specimens, but was not expressed in endothelium of pericarcinomatous liver tissue and normal liver tissue. Microvessel density (MVD) denoted by endocan (endocan-MVD) in HCC was correlated with microscopic venous invasion and VEGF expression (P < 0.05). Survival analysis showed that overall survival of patients was inversely associated with endocan-MVD (P < 0.01). Multivariate analysis showed that endocan-MVD was an independent prognostic marker for overall survival of HCC (P < 0.01). In conclusion, endocan-MVD was a significant factor to predict the prognosis of HCC patients after curative hepatectomy.

He J, Gu D, Wu X, Reynolds K, Duan X, Yao C et al (2005) Major causes of death among men and women in China. N Engl J Med 353:1124–1134. doi:10.1056/NEJMsa050467 PubMedCrossRef

Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C et al (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital death. Ann Surg 229:322–330. doi:10.1097/00000658-199903000-00004 PubMedCrossRef

Hubert C, Sempoux C, Rahier J, Horsmans Y, Geubel A, Van Beers BE et al (2007) Prognostic risk factors of survival after resection of hepatocellular carcinoma. Hepatogastroenterology 54(78):1791–1797PubMed

Ibrahim S, Roychowdhury A, Hean TK (2007) Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Am J Surg 194:17–22. doi:10.1016/j.amjsurg.2006.06.051 PubMedCrossRef

Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP (2007) Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 43:979–992. doi:10.1016/j.ejca.2007.01.004 PubMedCrossRef

Wang SM, Ooi LL, Hui KM (2007) Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 13:6275–6283. doi:10.1158/1078-0432.CCR-06-2236 PubMedCrossRef

Poon RTP, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24. doi:10.1097/00000658-200007000-00003 CrossRef

Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ et al (2004) Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90:2349–2355PubMed

Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X et al (2006) Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16:693–698PubMed

10.

Tanaka S, Arii S (2006) Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int J Clin Oncol 11:82–89. doi:10.1007/s10147-006-0566-5 PubMedCrossRef

11.

Huang GW, Yang LY, Lu WQ (2005) Expression of hypoxia-inducible factor 1 a and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 11:1705–1708PubMed

12.

Claudio PP, Russo G, Kumar CACY et al (2004) pRb2/p130, Vascular Endothelial Growth Factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma. Clin Cancer Res 10:3509–3517. doi:10.1158/1078-0432.CCR-03-0662 PubMedCrossRef

13.

Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N (2002) Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 8:3131–3136PubMed

14.

Poon RT, Ng IO, Lau C et al (2001) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298–304. doi:10.1016/S0002-9610(01)00708-5 PubMedCrossRef

15.

Poon RT, Ng IO, Lau C et al (2002) Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20:1775–1785. doi:10.1200/JCO.2002.07.089 PubMedCrossRef

16.

Wang SN, Chuang SC, Yeh YT et al (2006) Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol 59:1267–1271. doi:10.1136/jcp.2005.033464 PubMedCrossRef

17.

Yang LY, Lu WQ, Huang GW, Wang W (2006) Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 6:110. doi:10.1186/1471-2407-6-110

18.

Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochem Biophys Acta 1765:25–37PubMed

19.

van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. doi:10.1038/415530a PubMedCrossRef

20.

Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A et al (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64:844–856. doi:10.1158/0008-5472.CAN-03-2361 PubMedCrossRef

21.

Borczuk AC, Shah L, Pearson GD, Walter KL, Wang L, Austin JH et al (2004) Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 170:167–174. doi:10.1164/rccm.200401-066OC PubMedCrossRef

22.

Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T et al (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12:4575–4582. doi:10.1158/1078-0432.CCR-06-0185 PubMedCrossRef

23.

Huang GW, Yang LY (2002) Metallothionein expression in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 8:650–653PubMed

24.

Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180. doi:10.1007/BF00666038 PubMedCrossRef

25.

El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Iqarashi M, Yamamoto A et al (1998) Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27:1554–1562. doi:10.1002/hep. 510270613 PubMedCrossRef

26.

McDonald DM, Foss AJE (2000) Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 19:109–120. doi:10.1023/A:1026529222845 PubMedCrossRef

27.

Abid MR, Yi X, Yano K, Shih SC, Aird WC (2006) Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 72:136–145. doi:10.1016/j.mvr.2006.05.010 PubMedCrossRef

28.

Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423–435. doi:10.1038/nrc1628 PubMedCrossRef

29.

Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A et al (2007) Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 313:1285–1294. doi:10.1016/j.yexcr.2007.01.021 PubMedCrossRef

Title: Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma
Authors: Geng-Wen Huang
Yi-Ming Tao
Xiang Ding
Publication date: 01-02-2009
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 2/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0346-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Saline Infusion Through the Pancreatic Duct Leads to Changes in Calcium Homeostasis Similar to Those Observed in Acute Pancreatitis

Author’s Response to Letter to the Editor

The 3′UTR NFKBIA Variant Is Associated with Extensive Colitis in Hungarian IBD Patients

Study of the Association Between Polymorphisms of the COL1A1 Gene and HBV-Related Liver Cirrhosis in Chinese Patients

Diagnostic and Therapeutic Approach to Pancreatic Cancer-Associated Gastroparesis

CARD15/NOD2 Is Not a Predisposing Factor for Necrotizing Enterocolitis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page